TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03317652

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperventilation
Description: The subject is instructed to hyperventilate for 6 min to provoke a 0.7-1.2 kPa reduction in PaCO2, and the evaluation is repeated if the reduction in PaCO2 is not within this interval. The order of hyperventilation and 6% CO2 breathing is randomized.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6% CO2 breathing
Description: The subject breathes a mixture of 6% CO2 (with 21% O2 and 73% N2) from a bag and a face mask for 6 minutes. The order of hyperventilation and 6% CO2 breathing is randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infusion of sodium nitroprusside
Description: Using incremental intravenous infusion of sodium nitroprusside MAP is reduced by 20% (15%-25%) and then by 40% (35%-45%, MAP minimally at 50 mmHg).
Study: NCT04532164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butenafine HCl 1% (BAY1896425) - Induction Phase
Description: To each of two test sites, approximately 20 μl/cm\^2 of the Butenafine HCl 1% was applied directly to the skin and covered with a 25 mm Hilltop chamber with a Webril pad (2 cm in diameter, within an area of approximately 3 cm\^2), and tape was applied over the chamber to secure the occlusive patch to the skin. On the next day, the chambers were removed and both test sites were lightly wiped. Approximately 2 μl/cm\^2 of Butenafine HCl 1% was reapplied directly to the skin and lightly spread over the treated irradiated test site. The treated non-irradiated test site did not receive a similar reapplication. Between 5 and 15 minutes after application, the treated irradiated test site was irradiated with two times the subject's Minimal Erythema Dose (MED). Evaluation of the test sites occurred two days after the irradiation. This procedure was repeated two times per week for three consecutive weeks for a total of 6 induction exposures per test site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butenafine HCl 1% (BAY1896425) - Challenge Phase
Description: 5 μl/cm\^2 of the Butenafine HCl 1% was applied directly to each of the two virgin sites (treated sites) adjacent to the induction patch sites and covered with Hilltop chambers with Webril pad and tape was applied over the chambers to secure the occlusive patches to the skin. Two additional sites with no Butenafine HCl 1% (untreated sites) were also occluded. Sites were at least 2.5 cm apart. The patches were removed 24 hours later and the sites were lightly wiped. Test sites were evaluated. Butenafine HCl 1% (2 μl/cm\^2) was applied to the treated irradiated site. After 15 minutes, the treated irradiated site and the untreated irradiated site were irradiated with 0.5 MED of UVA/UVB irradiation followed by 10 Joules/cm\^2 of UVA from a xenon arc solar simulator equipped with a Schott WG345 to eliminate UVB radiation. The remaining sites served as the treated non-irradiated site and untreated non-irradiated site.
Study: NCT03590899

Intervention type: DEVICE
Intervention: Optical coherence tomography angiography (Zeiss Cirrus HD OCT 5000 AngioPlex)
Description: Non-invasive, non-contact optical coherence tomography angiography scans of the retina are done per built-in device protocol using the Zeiss Cirrus HD OCT 5000 AngioPlex machine.
Study: NCT00775866

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI-Guided Biopsy
Description: Technical development and clinical testing of a novel technique for magnetic resonance imaging (MRI) guided prostate biopsy in a 1.5T horizontal bore scanner using a dedicated interventional table.
Study: NCT02071134

Intervention type: DEVICE
Intervention: Deep Brain Stimulation (DBS)
Description: Subjects receiving Deep Brain Stimulation (DBS) for the treatment of their Parkinson's disease symptoms will be offered participation in this registry.
Study: NCT04798378

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurosleeve
Description: Myoelectric devices for restoration of independent arm function
Study: NCT00600353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Palonosetron 0.25 mg IV over 30 seconds

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Aprepitant 125 mg PO and Aprepitant 80 mg PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 4 mg IV and Dexamethasone 4 mg IV push
Study: NCT02457936

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy
Description: 8 weekly meetings in which basic mindfulness and meditation skills are taught, such as breathing meditation, body scan meditation, open awareness meditation, movement meditation, and targeting depression related cognitions and emotions in a mindful manner, as well as awareness exercises, group discussions, and daily home meditation practice routines
Study: NCT00720434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00868554
Description: 500 mg BID administered as 5x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00868554
Description: 300 mg BID administered as 3x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00868554
Description: 200 mg BID administered as 2x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks
Study: NCT02487693

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: Radiofrequency ablation is performed percutaneously under CT/US guidance

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-induced killer cells
Description: The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
Study: NCT02464462

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3 and calcium
Description: 1800 IU vitamin D3 plus 720 mg Calcium

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rice powder pills
Study: NCT00189254

Intervention type: DRUG
Intervention: Imiquimod
Description: No defined treatments were given during this study.
Study: NCT04459091

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino Essential Acid
Description: 8 gr die in two administration

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 8 gr die in two administration
Study: NCT02399501

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hysteroscopy
Description: Hysteroscopy is done under general anesthesia. The hysteroscopy used is rigid continuous flow diagnostic hysteroscopy (Tuttligen, Karl Storz, Germany). It has a 30º panoramic optic which is 4 mm in diameter and the diagnostic continuous flow outer sheath is 6.5 mm in diameter.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: two dimensional ultrasound
Description: Examination is performed after emptying of the bladder in dorsal lithotomy position .The probe is introduced into the posterior fornix of the vagina, then the following structures are examined, the uterus for site, size and mobility, the myometrium for fibroids and adenomyosis, the endometrium for uniformity, polyps, submucous fibroids and intrauterine adhesions, the cervix for nabothian follicles and polyps, the adenexa and ovaries for site, size, mobility, follicles, cysts and corpus luteum

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: saline sonohysterography
Description: sterile speculum is introduced and the vagina and cervix is cleaned with povidone iodine 10%. Cook ET (embryo transfer) catheter is used. . After introduction of the catheter into the cervix, a twenty milliliter syringe which will be prefilled with the distending media (saline) then fitted to the catheter. The speculum is removed and endovaginal probe is introduced in the posterior vaginal fornix

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: three dimensional ultrasound
Description: The uterus is visualized in the longitudinal plane, the ultrasound probe is kept steady and the patient is asked to lie still on the examination bed. The volume mode is switched on. Three D volume is generated by the automatic rotation of the mechanical transducer through 360º. The acquired volume is in the shape of a transacted cone with a depth of 4.3 - 8.6 cm and a vertical angle α = 90º. Using the medium line density, the typical acquisition time is a round 10 seconds
Study: NCT02457936

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Cognitive Therapy
Description: 8 weekly meetings in which basic mindfulness and meditation skills are taught, such as breathing meditation, body scan meditation, open awareness meditation, movement meditation, and targeting depression related cognitions and emotions in a mindful manner, as well as awareness exercises, group discussions, and daily home meditation practice routines
Study: NCT05634304

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A mobile app self-management (mSM) program
Description: The mSM program is developed on Bundura's self-efficacy theory, which provides four sources of information for SM. The strategies of the mSM consist of mobile app to management program including peer support, appraisal, goal setting and self-monitoring of exercise for OA and symptom management.
Study: NCT01633333

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water exchange colonoscopy
Description: Water is infused and suctioned in a systematic fashion to obtain luminal view and for cleansing of the colon to facilitate colonoscope insertion. The carbon dioxide pump is turned off, only to be turned on during withdrawal from the cecum.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carbon dioxide insufflation
Description: Carbon dioxide insufflation to obtain luminal view to facilitate colonoscope insertion, considered to be standard procedure.
Study: NCT04039815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic acid-Vitamin B1-Hydrocortisone
Description: intravenous Thiamine (200mg in 50 mL of 0.9% normal saline and was administered as a 30-min infusion every 12 hours for 4 days or until ICU discharge), plus Vitamin C (1.5g mixed in a 100-mL solution of normal saline and was administered as an infusion over 30 to 60 min every 6 hours for four days or until ICU discharge) as well as hydrocortisone 50mg every 6 hours (or other equivalent products) for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients would receive 50mL 0.9% normal saline, 100 mL 0.9% normal saline with the same infusion rate and hydrocortisone dependent on the discretion of the attending physician
Study: NCT02669381

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Phenylalanine intake
Description: Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
Study: NCT01896544

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 7ml syringe of cholecalciferol suspension given through nasogastric (NG) or orogastric (OG) tube

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 7ml syringe of cholecalciferol suspension given through nasogastric (NG) or orogastric (OG) tube

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7ml syringe of placebo cholecalciferol suspension given through nasogastric (NG) or orogastric (OG) tube
Study: NCT03152851

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pressure stimulus group
Study: NCT05809401

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pragmatic Rehabilitation
Description: A series of behavioral activities to improve specific pragmatic abilities in patients
Study: NCT03784014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Target: KIT, PDGFRA, CSF1R Nilotinib will be administered orally, 400 mg twice daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
Study: NCT05809401

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neuropsychological Rehabilitation
Description: A series of behavioral activities to improve general aspect of cognition, with a specific focus on attentional abilities.
Study: NCT04373135

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief educational video
Description: A brief educational video will be displayed explaining the mechanics of how SRA policies operate, how they are decided, and what patients' and healthcare workers' rights are surrounding them.
Study: NCT00007150

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Phlebotomy
Description: Therapeutic phlebotomy, the periodic, frequent removal of the iron contained in the hemoglobin of red blood cells.
Study: NCT05238714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venglustat
Description: Powder for Oral solution
Study: NCT01287390

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: video fluoroscopy
Description: video fluoroscopy of swallowing function at baseline, 6 months and 12 months follow-up

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: extra imaging
Description: For tumor response, 2 extra CT or Fludeoxyglucose (18F)-Positron Emission Tomography (PET)/Computed Tomography (CT), and/or Magnetic Resonance Imaging (MRI) will be performed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scoring acute toxicity
Description: Acute toxicity scoring, based on Common Toxicity criteria (CTC) version 2.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: scoring acute toxicity
Description: Acute toxicity scoring, based on Common Toxicity criteria (CTC) version 2.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scoring of late toxicity
Description: Scoring of late toxicity with the 'late effects in normal tissues subjective, objective, management and analytic'(LENT-SOMA) scale.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: scoring of late toxicity
Description: Scoring of late toxicity with the 'late effects in normal tissues subjective, objective, management and analytic'(LENT-SOMA) scale.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scoring quality of life (QOL)
Description: Quality of life is scored with the Quality of Life Questionnaire of the 'European Organisation for Research and Treatment of Cancer' (EORTC QOL-C30) and the Head and Neck Cancer Specific Quality of Life Questionnaire (QLQ-H\&N 35).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: scoring quality of life (QOL)
Description: Quality of life is scored with the Quality of Life Questionnaire of the 'European Organisation for Research and Treatment of Cancer' (EORTC QOL-C30) and the Head and Neck Cancer Specific Quality of Life Questionnaire (QLQ-H\&N 35).
Study: NCT03709745

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept Injection [Eylea]
Description: Intravitreal injection is given as described in the arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab Injection [Lucentis]
Description: Intravitreal injection is given as described in the arm description
Study: NCT01012960

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methylnaltrexone
Description: 0,15 mg/kg sc ( subcutaneously)once per volunteer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylnaltrexone
Description: 0,15 mg/kg sc ( subcutaneously)once per volunteer
Study: NCT02782780

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBTi)
Description: CBTi is a multicomponent treatment that seeks to teach patients about sleep and the factors that affect sleep (e.g., homeostatic regulation, circadian rhythm, age, social and work schedule) and to work with the patients toward minimizing unwanted arousal at bedtime and altering sleep habits to increase sleep propensity and regularity. The intervention is 8-weeks long.
Study: NCT03425123

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regenerative Endodontic Procedure (REP)
Description: Regenerative Endodontic Procedure (REP) involves disinfection of the root canal with the use of acombination of three antibiotics including ciprofloxacin, metronidazole, minocycline. At the second visit, the patient is evaluated for resolution of signs or symptoms of an acute infection and if none then bleeding is induced, the site covered with a plug and the patient is evaluated at follow up.
Study: NCT04023786

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP-TEST
Description: The PEEP test will consist of lowering the PEEP level to 5 cmH2O for a maximum of 2 minutes and a minimum of 1 minute. Patients will be included if the physicians who care for them have decided to set a baseline PEEP level ≥10 cmH2O.
Study: NCT02835508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56021927 60 Milligram
Description: JNJ-56021927 60 mg oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56021927 120 Milligram
Description: JNJ-56021927 120 mg as 2 tablets of 60 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56021927 240 Milligram
Description: JNJ-56021927 240 mg as 4 tablets of 60 mg.
Study: NCT01647815

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound measures
Description: Ultrasound will be used to measure the surfaces of the axillary and subclavian veins with the arms in different positions. Our goal is to compare the vein surface area available among different vein-position combinations. Our goal does not include testing specific devices.
Study: NCT04340401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: Patients will receive 3 cycles induction CapeOX and SHR-1210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: CapeOX is a combination chemotherapy regimen with OXA and CAPE, patients with high-risk rectal cancer will receive 3 cycles induction CapeOX and SHR-1210, intensity modulated radiotherapy with concurrent capecitabine and 2 cycles consolidation CapeOX and total mesorectal excision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: CapeOX is a combination chemotherapy regimen with OXA and CAPE, patients with high-risk rectal cancer will receive 3 cycles induction CapeOX and SHR-1210, intensity modulated radiotherapy with concurrent capecitabine and 2 cycles consolidation CapeOX and total mesorectal excision.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiotherapy
Description: patients will receive intensity modulated radiotherapy with capecitabine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total mesorectal excision
Description: Patients will receive TME (Total mesorectal excision) following TNT+SHR1210 if no metastasis occurs.
Study: NCT04271891

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WBPC
Description: The duration will be 30 minutes a time, and the frequency will be 5 days a week, and the treating period will be 3 weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Without WBPC
Description: Not treat with WBPC
Study: NCT03571269

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography-guided reperfusion strategy
Description: Optical coherence tomography will be used to detect the detailed characteristics of culprit lesion and to decide and optimize the reperfusion strategy according to the established algorithm in the protocol.
Study: NCT03063554

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Ultrasound Guided Biliary Drainage
Description: Endoscopic Ultrasound Guided biliary drainage with stent placement;

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: ERCP
Description: Endoscopic Retrograde Cholangiopancreatography with transpapillary biliary stent placement
Study: NCT01179854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remegal
Description: Drug/ placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remegal
Description: Drug/ placebo
Study: NCT02521103

Intervention type: DEVICE
Group type: OTHER
Intervention: Triathlon Tritanium Cone Augments
Description: The Triathlon Tritanium Cone Augments are an extension of the Triathlon Total Stabilizer (TS) system, intended to be used as an optional accessory component in primary or revision TKA
Study: NCT03642067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab was administered IV on day 1 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab was administered IV on day 1 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab was administered IV on day 1 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Relatlimab was administered IV on day 1 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Relatlimab was administered IV on day 1 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Relatlimab was administered IV on day 1 of each 28 day cycle.
Study: NCT04560673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Given PO
Study: NCT01916252

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bortezomib (Velcade ®)
Study: NCT01179854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remegal
Description: Drug/ placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remegal
Description: Drug/ placebo
Study: NCT02818686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04560673

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: Receive neurofeedback training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: Receive neurofeedback training